This means that passive immunization with tau antibodies can be a feasible therapeutic concentrate on and that the CSF level of p-tau262/356 or in the microtubule binding area (MTBD) can function a helpful biomarker of tau pathology to monitor tau therapeutics in clinical trials. A docking statio